Narcolepsie: Bibliography

Bibliography

2003A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy.: 2003, Feb.
Sleep, 26(1), 31-35.
Abrahamson2001Abrahamson, E. E., Leak, R. K. Moore, R. Y.: 2001, Feb.
The suprachiasmatic nucleus projects to posterior hypothalamic arousal systems.
Neuroreport, 12(2), 435-440.
Aguirre1985Aguirre, M., Broughton, R. Stuss, D.: 1985, Feb.
Does memory impairment exist in narcolepsy-cataplexy?
J Clin Exp Neuropsychol, 7(1), 14-24.
Aguirre1987Aguirre, M. Broughton, R. J.: 1987, Oct.
Complex event-related potentials (p300 and cnv) and mslt in the assessment of excessive daytime sleepiness in narcolepsy-cataplexy.
Electroencephalogr Clin Neurophysiol, 67(4), 298-316.
Akaoka1991Akaoka, H., Roussel, B., Lin, J. S., Chouvet, G. Jouvet, M.: 1991, Feb.
Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity.
Neurosci Lett, 123(1), 20-22.
AKIMOTO1960Akimoto, H., Honda, Y. Takahashi, Y.: 1960, Dec.
Pharmacotherapy in narcolepsy.
Dis Nerv Syst, 21, 704-706.
Alam1999Alam, M. N., Szymusiak, R., Gong, H., King, J. McGinty, D.: 1999, Dec.
Adenosinergic modulation of rat basal forebrain neurons during sleep and waking: neuronal recording with microdialysis.
J Physiol, 521 Pt 3, 679-690.
Aldrich1989Aldrich, M. S.: 1989, Dec.
Automobile accidents in patients with sleep disorders.
Sleep, 12(6), 487-494.
Aldrich1990Aldrich, M. S.: 1990, Aug.
Narcolepsy.
N Engl J Med, 323(6), 389-394.
Aldrich1996Aldrich, M. S.: 1996, Feb.
The clinical spectrum of narcolepsy and idiopathic hypersomnia.
Neurology, 46(2), 393-401.
Aldrich1997Aldrich, M. S., Chervin, R. D. Malow, B. A.: 1997, Aug.
Value of the multiple sleep latency test (mslt) for the diagnosis of narcolepsy.
Sleep, 20(8), 620-629.
Labat1999Anic-Labat, S., Guilleminault, C., Kraemer, H. C., Meehan, J., Arrigoni, J. Mignot, E.: 1999, Feb.
Validation of a cataplexy questionnaire in 983 sleep-disorders patients.
Sleep, 22(1), 77-87.
Autret2001Autret, A., Lucas, B., Mondon, K., Hommet, C., Corcia, P., Saudeau, D. .: 2001, Dec.
Sleep and brain lesions: a critical review of the literature and additional new cases.
Neurophysiol Clin, 31(6), 356-375.
Baker1982Baker, T. L., Foutz, A. S., McNerney, V., Mitler, M. M. Dement, W. C.: 1982, Mar.
Canine model of narcolepsy: genetic and developmental determinants.
Exp Neurol, 75(3), 729-742.
Baldwin2001Baldwin, C. M., Griffith, K. A., Nieto, F. J., O'Connor, G. T., Walsleben, J. A. Redline, S.: 2001, Feb.
The association of sleep-disordered breathing and sleep symptoms with quality of life in the sleep heart health study.
Sleep, 24(1), 96-105.
Banerjee2004Banerjee, D., Vitiello, M. V. Grunstein, R. R.: 2004, Oct.
Pharmacotherapy for excessive daytime sleepiness.
Sleep Med Rev, 8(5), 339-354.
Bassetti2003Bassetti, C., Gugger, M., Bischof, M., Mathis, J., Sturzenegger, C., Werth, E. .: 2003, Jan.
The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A).
Sleep Med, 4(1), 7-12.
Bastuji1988aBastuji, H. Jouvet, M.: 1988.
Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil.
Prog Neuropsychopharmacol Biol Psychiatry, 12(5), 695-700.
Baumann2005aBaumann, C. R. Bassetti, C. L.: 2005, Aug.
Hypocretins (orexins): clinical impact of the discovery of a neurotransmitter.
Sleep Med Rev, 9(4), 253-268.
BECK1961Beck, A. T., Ward, C. H., Mendelson, M., Mock, J. Erbaugh, J.: 1961, Jun.
An inventory for measuring depression.
Arch Gen Psychiatry, 4, 561-571.
Bell1986Bell, C. C., Dixie-Bell, D. D. Thompson, B.: 1986, Jul.
Further studies on the prevalence of isolated sleep paralysis in black subjects.
J Natl Med Assoc, 78(7), 649-659.
Bergner1981Bergner, M., Bobbitt, R. A., Carter, W. B. Gilson, B. S.: 1981, Aug.
The sickness impact profile: development and final revision of a health status measure.
Med Care, 19(8), 787-805.
Bernasconi1999Bernasconi, R., Mathivet, P., Bischoff, S. Marescaux, C.: 1999, Apr.
Gamma-hydroxybutyric acid: an endogenous neuromodulator with abuse potential?
Trends Pharmacol Sci, 20(4), 135-141.
Besset1996aBesset, A., Chetrit, M., Carlander, B. Billiard, M.: 1996.
Use of modafinil in the treatment of narcolepsy: a long term follow-up study.
Neurophysiol Clin, 26(1), 60-66.
Beuckmann2004Beuckmann, C. T., Sinton, C. M., Williams, S. C., Richardson, J. A., Hammer, R. E., Sakurai, T. .: 2004, May.
Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat.
J Neurosci, 24(18), 4469-4477.
Beusterien1999Beusterien, K. M., Rogers, A. E., Walsleben, J. A., Emsellem, H. A., Reblando, J. A., Wang, L. .: 1999, Sep.
Health-related quality of life effects of modafinil for treatment of narcolepsy.
Sleep, 22(6), 757-765.
Billiard1994Billiard, M., Pasquié-Magnetto, V., Heckman, M., Carlander, B., Besset, A., Zachariev, Z. .: 1994, Dec.
Family studies in narcolepsy.
Sleep, 17(8 Suppl), S54-S59.
Billiard1986aBilliard, M., Seignalet, J., Besset, A. Cadilhac, J.: 1986.
HLA-DR2 and narcolepsy.
Sleep, 9(1 Pt 2), 149-152.
Boehme1984aBoehme, R. E., Baker, T. L., Mefford, I. N., Barchas, J. D., Dement, W. C. Ciaranello, R. D.: 1984, May.
Narcolepsy: cholinergic receptor changes in an animal model.
Life Sci, 34(19), 1825-1828.
Borbely1977Borbely, A. A.: 1977, Apr.
Sleep in the rat during food deprivation and subsequent restitution of food.
Brain Res, 124(3), 457-471.
Borbely1982Borbely, A. A.: 1982.
A two process model of sleep regulation.
Hum Neurobiol, 1(3), 195-204.
Bowersox1987Bowersox, S. S., Kilduff, T. S., Faull, K. F., Zeller-DeAmicis, L., Dement, W. C. Ciaranello, R. D.: 1987, Jan.
Brain dopamine receptor levels elevated in canine narcolepsy.
Brain Res, 402(1), 44-48.
Brazier1993aBrazier, J., Jones, N. Kind, P.: 1993, Jun.
Testing the validity of the euroqol and comparing it with the sf-36 health survey questionnaire.
Qual Life Res, 2(3), 169-180.
Briones1996Briones, B., Adams, N., Strauss, M., Rosenberg, C., Whalen, C., Carskadon, M. .: 1996, Sep.
Relationship between sleepiness and general health status.
Sleep, 19(7), 583-588.
BRODIE1961Brodie, B., Dick, P., Kielholz, P., Poedinger, W. Theobald, W.: 1961, Dec.
Preliminary pharmacological and clinical results with desmethylimipramine (dmi) g 35020, a metabolite of imipramine.
Psychopharmacologia, 2, 467-474.
Broughton1988Broughton, R., Dunham, W., Newman, J., Lutley, K., Duschesne, P. Rivers, M.: 1988, Dec.
Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched controls.
Electroencephalogr Clin Neurophysiol, 70(6), 473-481.
Broughton1981Broughton, R., Ghanem, Q., Hishikawa, Y., Sugita, Y., Nevsimalova, S. Roth, B.: 1981, Nov.
Life effects of narcolepsy in 180 patients from north america, asia and europe compared to matched controls.
Can J Neurol Sci, 8(4), 299-304.
Broughton1983Broughton, R., Ghanem, Q., Hishikawa, Y., Sugita, Y., Nevsimalova, S. Roth, B.: 1983, May.
Life effects of narcolepsy: relationships to geographic origin (north american, asian or european) and to other patient and illness variables.
Can J Neurol Sci, 10(2), 100-104.
Broughton1979Broughton, R. Mamelak, M.: 1979, Feb.
The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate.
Can J Neurol Sci, 6(1), 1-6.
Broughton1980Broughton, R. Mamelak, M.: 1980, Feb.
Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy.
Can J Neurol Sci, 7(1), 23-31.
Broughton1997Broughton, R. J., Fleming, J. A., George, C. F., Hill, J. D., Kryger, M. H., Moldofsky, H. .: 1997, Aug.
Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy.
Neurology, 49(2), 444-451.
Broughton1984Broughton, R. J., Guberman, A. Roberts, J.: 1984, Aug.
Comparison of the psychosocial effects of epilepsy and narcolepsy/cataplexy: a controlled study.
Epilepsia, 25(4), 423-433.
Broughton1994Broughton, W. A. Broughton, R. J.: 1994, Dec.
Psychosocial impact of narcolepsy.
Sleep, 17(8 Suppl), S45-S49.
Browman1983aBrowman, C. P., Gujavarty, K. S., Sampson, M. G. Mitler, M. M.: 1983.
Rem sleep episodes during the maintenance of wakefulness test in patients with sleep apnea syndrome and patients with narcolepsy.
Sleep, 6(1), 23-28.
Browman1986Browman, C. P., Gujavarty, K. S., Yolles, S. F. Mitler, M. M.: 1986.
Forty-eight-hour polysomnographic evaluation of narcolepsy.
Sleep, 9(1 Pt 2), 183-188.
Brown2001Brown, R. E., Sergeeva, O., Eriksson, K. S. Haas, H. L.: 2001, Mar.
Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat.
Neuropharmacology, 40(3), 457-459.
Browne1994Browne, J. P., O'Boyle, C. A., McGee, H. M., Joyce, C. R., McDonald, N. J., O'Malley, K. .: 1994, Aug.
Individual quality of life in the healthy elderly.
Qual Life Res, 3(4), 235-244.
Burrow2005aBurrow, B., Burkle, C., Warner, D. O. Chini, E. N.: 2005, Feb.
Postoperative outcome of patients with narcolepsy. a retrospective analysis.
J Clin Anesth, 17(1), 21-25.
Carlander1993Carlander, B., Eliaou, J. F. Billiard, M.: 1993, Jan.
Autoimmune hypothesis in narcolepsy.
Neurophysiol Clin, 23(1), 15-22.
Carskadon1987Carskadon, M. A. Dement, W. C.: 1987.
Daytime sleepiness: quantification of a behavioral state.
Neurosci Biobehav Rev, 11(3), 307-317.
Carskadon1986Carskadon, M. A., Dement, W. C., Mitler, M. M., Roth, T., Westbrook, P. R. Keenan, S.: 1986, Dec.
Guidelines for the multiple sleep latency test (mslt): a standard measure of sleepiness.
Sleep, 9(4), 519-524.
Challamel1994Challamel, M. J., Mazzola, M. E., Nevsimalova, S., Cannard, C., Louis, J. Revol, M.: 1994, Dec.
Narcolepsy in children.
Sleep, 17(8 Suppl), S17-S20.
Challet1997Challet, E., Pevet, P. Malan, A.: 1997, Mar.
Effect of prolonged fasting and subsequent refeeding on free-running rhythms of temperature and locomotor activity in rats.
Behav Brain Res, 84(1-2), 275-284.
Challman2000Challman, T. D. Lipsky, J. J.: 2000, Jul.
Methylphenidate: its pharmacology and uses.
Mayo Clin Proc, 75(7), 711-721.
Chemelli1999Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C. .: 1999, Aug.
Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.
Cell, 98(4), 437-451.
Chou2001Chou, T. C., Lee, C. E., Lu, J., Elmquist, J. K., Hara, J., Willie, J. T. .: 2001, Oct.
Orexin (hypocretin) neurons contain dynorphin.
J Neurosci, 21(19), RC168.
Daan1984Daan, S., Beersma, D. G. Borbély, A. A.: 1984, Feb.
Timing of human sleep: recovery process gated by a circadian pacemaker.
Am J Physiol, 246(2 Pt 2), R161-R183.
Dahl1994Dahl, R. E., Holttum, J. Trubnick, L.: 1994.
A clinical picture of child and adolescent narcolepsy.
J Am Acad Child Adolesc Psychiatry, 33(6), 834-841.
Danguir1979Danguir, J. Nicolaidis, S.: 1979, Apr.
Dependence of sleep on nutrients' availability.
Physiol Behav, 22(4), 735-740.
Daniels2001Daniels, E., King, M. A., Smith, I. E. Shneerson, J. M.: 2001, Mar.
Health-related quality of life in narcolepsy.
J Sleep Res, 10(1), 75-81.
Dantz1994Dantz, B., Edgar, D. M. Dement, W. C.: 1994, Jan.
Circadian rhythms in narcolepsy: studies on a 90 minute day.
Electroencephalogr Clin Neurophysiol, 90(1), 24-35.
Date1999Date, Y., Ueta, Y., Yamashita, H., Yamaguchi, H., Matsukura, S., Kangawa, K. .: 1999, Jan.
Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems.
Proc Natl Acad Sci U S A, 96(2), 748-753.
Dauvilliers2004aDauvilliers, Y., Maret, S., Bassetti, C., Carlander, B., Billiard, M., Touchon, J. .: 2004, Jun.
A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1.
Neurology, 62(11), 2137-2138.
Dauvilliers2005Dauvilliers, Y., Maret, S. Tafti, M.: 2005, Apr.
Genetics of normal and pathological sleep in humans.
Sleep Med Rev, 9(2), 91-100.
Dauvilliers2001Dauvilliers, Y., Neidhart, E., Lecendreux, M., Billiard, M. Tafti, M.: 2001, Jul.
MAO-A and COMT polymorphisms and gene effects in narcolepsy.
Mol Psychiatry, 6(4), 367-372.
Deboer2004Deboer, T., Overeem, S., Visser, N. A. H., Duindam, H., Frölich, M., Lammers, G. J. .: 2004.
Convergence of circadian and sleep regulatory mechanisms on hypocretin-1.
Neuroscience, 129(3), 727-732.
DEMENT1957Dement, W. Kleitman, N.: 1957, Nov.
Cyclic variations in EEG during sleep and their relation to eye movements, body motility, and dreaming.
Electroencephalogr Clin Neurophysiol Suppl, 9(4), 673-690.
Dewasmes1989Dewasmes, G., Duchamp, C. Minaire, Y.: 1989, Aug.
Sleep changes in fasting rats.
Physiol Behav, 46(2), 179-184.
Dickstein1999Dickstein, J. B. Moldofsky, H.: 1999, Sep.
Sleep, cytokines and immune function.
Sleep Med Rev, 3(3), 219-228.
Dijk1994Dijk, D. J. Czeisler, C. A.: 1994, Jan.
Paradoxical timing of the circadian rhythm of sleep propensity serves to consolidate sleep and wakefulness in humans.
Neurosci Lett, 166(1), 63-68.
Doghramji1997Doghramji, K., Mitler, M. M., Sangal, R. B., Shapiro, C., Taylor, S., Walsleben, J. .: 1997, Nov.
A normative study of the maintenance of wakefulness test (mwt).
Electroencephalogr Clin Neurophysiol, 103(5), 554-562.
Douglas1998bDouglas, N. J.: 1998, Feb.
The psychosocial aspects of narcolepsy.
Neurology, 50(2 Suppl 1), S27-S30.
Dube1999Dube, M. G., Kalra, S. P. Kalra, P. S.: 1999, Sep.
Food intake elicited by central administration of orexins/hypocretins: identification of hypothalamic sites of action.
Brain Res, 842(2), 473-477.
Edgar1993Edgar, D. M., Dement, W. C. Fuller, C. A.: 1993, Mar.
Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation.
J Neurosci, 13(3), 1065-1079.
Ad1998El-Ad, B. Korczyn, A. D.: 1998, Jan.
Disorders of excessive daytime sleepiness-an update.
J Neurol Sci, 153(2), 192-202.
Ellison1978Ellison, G., Eison, M. S., Huberman, H. S. Daniel, F.: 1978, Jul.
Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration.
Science, 201(4352), 276-278.
Elmquist1999Elmquist, J. K., Elias, C. F. Saper, C. B.: 1999, Feb.
From lesions to leptin: hypothalamic control of food intake and body weight.
Neuron, 22(2), 221-232.
Engber1998Engber, T. M., Dennis, S. A., Jones, B. E., Miller, M. S. Contreras, P. C.: 1998, Dec.
Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine.
Neuroscience, 87(4), 905-911.
Erlich1986Erlich, S. S. Itabashi, H. H.: 1986.
Narcolepsy: a neuropathologic study.
Sleep, 9(1 Pt 2), 126-132.
Estabrooke2001Estabrooke, I. V., McCarthy, M. T., Ko, E., Chou, T. C., Chemelli, R. M., Yanagisawa, M. .: 2001, Mar.
Fos expression in orexin neurons varies with behavioral state.
J Neurosci, 21(5), 1656-1662.
1990Euroqol-a new facility for the measurement of health-related quality of life. the euroqol group.: 1990, Dec.
Health Policy, 16(3), 199-208.
Faraj1974Faraj, B. A., Israili, Z. H., Perel, J. M., Jenkins, M. L., Holtzman, S. G., Cucinell, S. A. .: 1974, Dec.
Metabolism and disposition of methylphenidate-14c: studies in man and animals.
J Pharmacol Exp Ther, 191(3), 535-547.
Fernandez-Vina1991aFernandez-Vina, M. A., Gao, X. J., Moraes, M. E., Moraes, J. R., Salatiel, I., Miller, S. .: 1991.
Alleles at four hla class ii loci determined by oligonucleotide hybridization and their associations in five ethnic groups.
Immunogenetics, 34(5), 299-312.
Ferrans1985Ferrans, C. E. Powers, M. J.: 1985, Oct.
Quality of life index: development and psychometric properties.
ANS Adv Nurs Sci, 8(1), 15-24.
Ferraro1999Ferraro, L., Antonelli, T., Tanganelli, S., O'Connor, W. T., Mora, M. P. de la, Mendez-Franco, J. .: 1999, Apr.
The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade.
Neuropsychopharmacology, 20(4), 346-356.
Ferraro1996Ferraro, L., Tanganelli, S., O'Connor, W. T., Antonelli, T., Rambert, F. Fuxe, K.: 1996, Dec.
The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor.
Neurosci Lett, 220(1), 5-8.
Findley1995Findley, L., Unverzagt, M., Guchu, R., Fabrizio, M., Buckner, J. Suratt, P.: 1995, Sep.
Vigilance and automobile accidents in patients with sleep apnea or narcolepsy.
Chest, 108(3), 619-624.
Findley1999Findley, L. J., Suratt, P. M. Dinges, D. F.: 1999, Sep.
Time-on-task decrements in "steer clear" performance of patients with sleep apnea and narcolepsy.
Sleep, 22(6), 804-809.
Frey1994Frey, J. Darbonne, C.: 1994, Apr.
Fluoxetine suppresses human cataplexy: a pilot study.
Neurology, 44(4), 707-709.
Fry1998jFry, J. M.: 1998, Feb.
Treatment modalities for narcolepsy.
Neurology, 50(2 Suppl 1), S43-S48.
Fry1986Fry, J. M., Pressman, M. R., DiPhillipo, M. A. Forst-Paulus, M.: 1986.
Treatment of narcolepsy with codeine.
Sleep, 9(1 Pt 2), 269-274.
Fujiki2006Fujiki, N., Yoshida, Y., Zhang, S., Sakurai, T., Yanagisawa, M. Nishino, S.: 2006, Sep.
Sex difference in body weight gain and leptin signaling in hypocretin/orexin deficient mouse models.
Peptides, 27(9), 2326-2331.
Fulda2001Fulda, S. Schulz, H.: 2001, Dec.
Cognitive dysfunction in sleep disorders.
Sleep Med Rev, 5(6), 423-445.
Fuller1980Fuller, R. W. Hemrick-Luecke, S.: 1980, Jul.
Long-lasting depletion of striatal dopamine by a single injection of amphetamine in iprindole-treated rats.
Science, 209(4453), 305-307.
Furuta2001bFuruta, H., Thorpy, M. J. Temple, H. M.: 2001, Jun.
Comparison in symptoms between aged and younger patients with narcolepsy.
Psychiatry Clin Neurosci, 55(3), 241-242.
Gallopin2004Gallopin, T., Luppi, P.-H., Rambert, F. A., Frydman, A. Fort, P.: 2004, Feb.
Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study.
Sleep, 27(1), 19-25.
Gautvik1996Gautvik, K. M., Lecea, L. de, Gautvik, V. T., Danielson, P. E., Tranque, P., Dopazo, A. .: 1996, Aug.
Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction.
Proc Natl Acad Sci U S A, 93(16), 8733-8738.
Gelineau1880Gelineau.: 1880.
De la narcolepsie.
Gazette des Hospitaux, 53, 626-628.
George1996George, C. F., Boudreau, A. C. Smiley, A.: 1996, Nov.
Comparison of simulated driving performance in narcolepsy and sleep apnea patients.
Sleep, 19(9), 711-717.
Gillin1983Gillin, J. C.: 1983.
The sleep therapies of depression.
Prog Neuropsychopharmacol Biol Psychiatry, 7(2-3), 351-364.
Godbout1986Godbout, R. Montplaisir, J.: 1986.
All-day performance variations in normal and narcoleptic subjects.
Sleep, 9(1 Pt 2), 200-204.
GOODE1962Goode, G. B.: 1962, Mar.
Sleep paralysis.
Arch Neurol, 6, 228-234.
Goswami1998Goswami, M.: 1998, Feb.
The influence of clinical symptoms on quality of life in patients with narcolepsy.
Neurology, 50(2 Suppl 1), S31-S36.
Govindaiah2006Govindaiah, G. Cox, C. L.: 2006, Sep.
Modulation of thalamic neuron excitability by orexins.
Neuropharmacology, 51(3), 414-425.
Green1998Green, P. M. Stillman, M. J.: 1998.
Narcolepsy. signs, symptoms, differential diagnosis, and management.
Arch Fam Med, 7(5), 472-478.
Guilleminault1989Guilleminault, C., Mignot, E. Grumet, F. C.: 1989, Dec.
Familial patterns of narcolepsy.
Lancet, 2(8676), 1376-1379.
Guilleminault1994Guilleminault, C., Mignot, E. Partinen, M.: 1994, Dec.
Controversies in the diagnosis of narcolepsy.
Sleep, 17(8 Suppl), S1-S6.
Guilleminault1998Guilleminault, C. Pelayo, R.: 1998, Jan.
Narcolepsy in prepubertal children.
Ann Neurol, 43(1), 135-142.
Gulyani2002Gulyani, S., Wu, M.-F., Nienhuis, R., John, J. Siegel, J. M.: 2002.
Cataplexy-related neurons in the amygdala of the narcoleptic dog.
Neuroscience, 112(2), 355-365.
Hagan1999Hagan, J. J., Leslie, R. A., Patel, S., Evans, M. L., Wattam, T. A., Holmes, S. .: 1999, Sep.
Orexin A activates locus coeruleus cell firing and increases arousal in the rat.
Proc Natl Acad Sci U S A, 96(19), 10911-10916.
Hara2001Hara, J., Beuckmann, C. T., Nambu, T., Willie, J. T., Chemelli, R. M., Sinton, C. M. .: 2001, May.
Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.
Neuron, 30(2), 345-354.
Hartse1988Hartse, K. M., Zorick, F. J., Sicklesteel, J. M. Roth, T.: 1988.
Isolated cataplexy: a familial study.
Henry Ford Hosp Med J, 36(1), 24-27.
Hellriegel2001Hellriegel, E. T., Arora, S., Nelson, M. Robertson, P.: 2001, Aug.
Steady-state pharmacokinetics and tolerability of modafinil given alone or in combination with methylphenidate in healthy volunteers.
J Clin Pharmacol, 41(8), 895-904.
Hellriegel2002Hellriegel, E. T., Arora, S., Nelson, M. Robertson, P.: 2002, Apr.
Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers.
J Clin Pharmacol, 42(4), 450-460.
Helmus1996Helmus, T., Rosenthal, L., Bishop, C., Roehrs, T., Krsevska, S. Roth, T.: 1996, Jul.
Nocturnal sleep latencies among alert, alert-deprived and sleepy subjects.
Electroencephalogr Clin Neurophysiol, 99(1), 10-15.
Henry1988Henry, G. K., Hart, R. P., Kwentus, J. A. Sicola, M. J.: 1988.
Effects of protriptyline on vigilance and information processing in narcolepsy.
Psychopharmacology (Berl), 95(1), 109-112.
Henry1993Henry, G. K., Satz, P. Heilbronner, R. L.: 1993, Feb.
Evidence of a perceptual-encoding deficit in narcolepsy?
Sleep, 16(2), 123-127.
Higuchi2002Higuchi, S., Usui, A., Murasaki, M., Matsushita, S., Nishioka, N., Yoshino, A. .: 2002, Jan.
Plasma orexin-A is lower in patients with narcolepsy.
Neurosci Lett, 318(2), 61-64.
Hishikawa1966Hishikawa, Y., Ida, H., Nakai, K. Kaneko, Z.: 1966.
Treatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran).
J Neurol Sci, 3(5), 453-461.
Hishikawa1976Hishikawa, Y., Wakamatsu, H., Furuya, E., Sugita, Y. Masaoka, S.: 1976, Jul.
Sleep satiation in narcoleptic patients.
Electroencephalogr Clin Neurophysiol, 41(1), 1-18.
Hohjoh2000Hohjoh, H., Terada, N., Kawashima, M., Honda, Y. Tokunaga, K.: 2000, Nov.
Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with human narcolepsy.
Tissue Antigens, 56(5), 446-448.
Holmes1995Holmes, V. F.: 1995.
Medical use of psychostimulants: an overview.
Int J Psychiatry Med, 25(1), 1-19.
Honda1986cHonda, Y., Doi, Y., Ninomiya, R. Ninomiya, C.: 1986.
Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients.
Sleep, 9(1 Pt 2), 254-259.
Hood1996Hood, B. Bruck, D.: 1996, Jun.
Sleepiness and performance in narcolepsy.
J Sleep Res, 5(2), 128-134.
Hood1997Hood, B. Bruck, D.: 1997, Sep.
Metamemory in narcolepsy.
J Sleep Res, 6(3), 205-210.
Hood2002Hood, B. Bruck, D.: 2002, May.
A comparison of sleep deprivation and narcolepsy in terms of complex cognitive performance and subjective sleepiness.
Sleep Med, 3(3), 259-266.
Hublin1994cHublin, Kaprio, Partinen, Koskenvuo Heikkilä.: 1994, Mar.
The ullanlinna narcolepsy scale: validation of a measure of symptoms in the narcoleptic syndrome.
J Sleep Res, 3(1), 52-59.
Hublin1994bHublin, C., Kaprio, J., Partinen, M., Koskenvuo, M., Heikkila, K., Koskimies, S. .: 1994, Jun.
The prevalence of narcolepsy: an epidemiological study of the finnish twin cohort.
Ann Neurol, 35(6), 709-716.
Hungs2001aHungs, M. Mignot, E.: 2001, May.
Hypocretin/orexin, sleep and narcolepsy.
Bioessays, 23(5), 397-408.
Hunt1985fHunt, S. M., McEwen, J. McKenna, S. P.: 1985, Apr.
Measuring health status: a new tool for clinicians and epidemiologists.
J R Coll Gen Pract, 35(273), 185-188.
Ishizuka2003Ishizuka, T., Sakamoto, Y., Sakurai, T. Yamatodani, A.: 2003, Mar.
Modafinil increases histamine release in the anterior hypothalamus of rats.
Neurosci Lett, 339(2), 143-146.
Itoh1990Itoh, T., Murai, S., Nagahama, H., Miyate, H., Abe, E., Fujiwara, H. .: 1990, Feb.
Effects of 24-hr fasting on methamphetamine- and apomorphine-induced locomotor activities, and on monoamine metabolism in mouse corpus striatum and nucleus accumbens.
Pharmacol Biochem Behav, 35(2), 391-396.
Ivanenko2003Ivanenko, A., Tauman, R. Gozal, D.: 2003, Nov.
Modafinil in the treatment of excessive daytime sleepiness in children.
Sleep Med, 4(6), 579-582.
Jacobs1991Jacobs, B. L. Fornal, C. A.: 1991, Dec.
Activity of brain serotonergic neurons in the behaving animal.
Pharmacol Rev, 43(4), 563-578.
Janjua2003Janjua, T., Samp, T., Cramer-Bornemann, M., Hannon, H. Mahowald, M. W.: 2003, Jan.
Clinical caveat: prior sleep deprivation can affect the mslt for days.
Sleep Med, 4(1), 69-72.
Jasinski2000bJasinski, D. R.: 2000, Mar.
An evaluation of the abuse potential of modafinil using methylphenidate as a reference.
J Psychopharmacol, 14(1), 53-60.
Jasinski2000Jasinski, D. R. Kovacevic-Ristanovic, R.: 2000.
Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy.
Clin Neuropharmacol, 23(3), 149-156.
Jean-Louis2000Jean-Louis, G., Kripke, D. F. Ancoli-Israel, S.: 2000, Dec.
Sleep and quality of well-being.
Sleep, 23(8), 1115-1121.
Jenkinson1998aJenkinson, C., Stradling, J. Petersen, S.: 1998, Feb.
How should we evaluate health status? a comparison of three methods in patients presenting with obstructive sleep apnoea.
Qual Life Res, 7(2), 95-100.
John2003John, J., Wu, M.-F., Kodama, T. Siegel, J. M.: 2003, Apr.
Intravenously administered hypocretin-1 alters brain amino acid release: an in vivo microdialysis study in rats.
J Physiol, 548(Pt 2), 557-562.
John2000John, J., Wu, M. F. Siegel, J. M.: 2000.
Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs.
Sleep Res Online, 3(1), 23-28.
Johns1994Johns, M. W.: 1994, Dec.
Sleepiness in different situations measured by the epworth sleepiness scale.
Sleep, 17(8), 703-710.
Jouvet1967Jouvet, M.: 1967, Apr.
Neurophysiology of the states of sleep.
Physiol Rev, 47(2), 117-177.
Kales1982bKales, A., Cadieux, R. J., Soldatos, C. R., Bixler, E. O., Schweitzer, P. K., Prey, W. T. .: 1982, Mar.
Narcolepsy-cataplexy. I. Clinical and electrophysiologic characteristics.
Arch Neurol, 39(3), 164-168.
Kales1985Kales, A., Caldwell, A. B., Cadieux, R. J., Vela-Bueno, A., Ruch, L. G. Mayes, S. D.: 1985.
Severe obstructive sleep apnea-ii: Associated psychopathology and psychosocial consequences.
J Chronic Dis, 38(5), 427-434.
Kales1982aKales, A., Soldatos, C. R., Bixler, E. O., Caldwell, A., Cadieux, R. J., Verrechio, J. M. .: 1982, Mar.
Narcolepsy-cataplexy. ii. psychosocial consequences and associated psychopathology.
Arch Neurol, 39(3), 169-171.
Kandt1982Kandt, R. S., Emerson, R. G., Singer, H. S., Valle, D. L. Moser, H. W.: 1982, Sep.
Cataplexy in variant forms of Niemann-Pick disease.
Ann Neurol, 12(3), 284-288.
Kastin1999aKastin, A. J. Akerstrom, V.: 1999, Apr.
Orexin A but not orexin B rapidly enters brain from blood by simple diffusion.
J Pharmacol Exp Ther, 289(1), 219-223.
Khatami2004Khatami, R., Maret, S., Werth, E., Rétey, J., Schmid, D., Maly, F. .: 2004, Apr.
Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway.
Lancet, 363(9416), 1199-1200.
Kilduff2000Kilduff, T. S. Peyron, C.: 2000, Aug.
The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders.
Trends Neurosci, 23(8), 359-365.
Kiyashchenko2001Kiyashchenko, L. I., Mileykovskiy, B. Y., Lai, Y. Y. Siegel, J. M.: 2001, May.
Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area.
J Neurophysiol, 85(5), 2008-2016.
Klein2000Klein, J. Sato, A.: 2000, Sep.
The HLA system. Second of two parts.
N Engl J Med, 343(11), 782-786.
Knoll1983Knoll, J.: 1983.
Deprenyl (selegiline): the history of its development and pharmacological action.
Acta Neurol Scand Suppl, 95, 57-80.
Kok2002aKok, S. W., Meinders, A. E., Overeem, S., Lammers, G. J., Roelfsema, F., Frölich, M. .: 2002, Feb.
Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin (orexin)-deficient narcoleptic humans.
J Clin Endocrinol Metab, 87(2), 805-809.
Koran1993Koran, L. M. Raghavan, S.: 1993.
Fluoxetine for isolated sleep paralysis.
Psychosomatics, 34(2), 184-187.
Kotterba2004Kotterba, S., Mueller, N., Leidag, M., Widdig, W., Rasche, K., Malin, J.-P. .: 2004, Sep.
Comparison of driving simulator performance and neuropsychological testing in narcolepsy.
Clin Neurol Neurosurg, 106(4), 275-279.
Kotterba1998Kotterba, S., Rasche, K., Widdig, W., Duscha, C., Blombach, S., Schultze-Werninghaus, G. .: 1998, Jul.
Neuropsychological investigations and event-related potentials in obstructive sleep apnea syndrome before and during cpap-therapy.
J Neurol Sci, 159(1), 45-50.
Krettek1978aKrettek, J. E. Price, J. L.: 1978, Mar.
Amygdaloid projections to subcortical structures within the basal forebrain and brainstem in the rat and cat.
J Comp Neurol, 178(2), 225-254.
Lammers1996aLammers, G. J., Pijl, H., Iestra, J., Langius, J. A., Buunk, G. Meinders, A. E.: 1996, Jan.
Spontaneous food choice in narcolepsy.
Sleep, 19(1), 75-76.
Landi1999Landi, M. T., Sinha, R., Lang, N. P. Kadlubar, F. F.: 1999.
Human cytochrome p4501a2.
IARC Sci Publ(148), 173-195.
Langdon1984Langdon, N., Welsh, K. I., Dam, M. van, Vaughan, R. W. Parkes, D.: 1984, Nov.
Genetic markers in narcolepsy.
Lancet, 2(8413), 1178-1180.
Lankford1994Lankford, D. A., Wellman, J. J. O'Hara, C.: 1994, Dec.
Posttraumatic narcolepsy in mild to moderate closed head injury.
Sleep, 17(8 Suppl), S25-S28.
Lecea1998Lecea, L. de, Kilduff, T. S., Peyron, C., Gao, X., Foye, P. E., Danielson, P. E. .: 1998, Jan.
The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.
Proc Natl Acad Sci U S A, 95(1), 322-327.
Leibowitz1998Leibowitz, S. F. Alexander, J. T.: 1998, Nov.
Hypothalamic serotonin in control of eating behavior, meal size, and body weight.
Biol Psychiatry, 44(9), 851-864.
Levander1985aLevander, S. Sachs, C.: 1985, Jan.
Vigilance performance and autonomic function in narcolepsy: effects of central stimulants.
Psychophysiology, 22(1), 24-31.
Lin1996Lin, J. S., Hou, Y. Jouvet, M.: 1996, Nov.
Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat.
Proc Natl Acad Sci U S A, 93(24), 14128-14133.
Lin1999Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X. .: 1999, Aug.
The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.
Cell, 98(3), 365-376.
Lin2001Lin, L., Hungs, M. Mignot, E.: 2001, Jul.
Narcolepsy and the HLA region.
J Neuroimmunol, 117(1-2), 9-20.
Littner2001aLittner, M., Johnson, S. F., McCall, W. V., Anderson, W. M., Davila, D., Hartse, S. K. .: 2001, Jun.
Practice parameters for the treatment of narcolepsy: an update for 2000.
Sleep, 24(4), 451-466.
Mamelak1986Mamelak, M., Scharf, M. B. Woods, M.: 1986.
Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings.
Sleep, 9(1 Pt 2), 285-289.
Mamelak1981Mamelak, M. Webster, P.: 1981.
Treatment of narcolepsy and sleep apnea with gammahydroxybutyrate: a clinical and polysomnographic case study.
Sleep, 4(1), 105-111.
Manni2001Manni, R., Politini, L., Nobili, L., Ferrillo, F., Livieri, C., Veneselli, E. .: 2001, May.
Hypersomnia in the Prader Willi syndrome: clinical-electrophysiological features and underlying factors.
Clin Neurophysiol, 112(5), 800-805.
Marotta1998Marotta, P. J. Roberts, E. A.: 1998, May.
Pemoline hepatotoxicity in children.
J Pediatr, 132(5), 894-897.
Martinez-Rodriguez2005Martinez-Rodriguez, J. E. Santamaria, J.: 2005, Dec.
Csf markers in sleep neurobiology.
Clin Chim Acta, 362(1-2), 12-25.
Mayer1997Mayer, G., Hellmann, F., Leonhard, E. Meier-Ewert, K.: 1997, Oct.
Circadian temperature and activity rhythms in unmedicated narcoleptic patients.
Pharmacol Biochem Behav, 58(2), 395-402.
McCarley1992McCarley Massaquoi.: 1992, Jun.
Neurobiological structure of the revised limit cycle reciprocal interaction model of REM cycle control.
J Sleep Res, 1(2), 132-137.
McHorney1994McHorney, C. A., Ware, J. E., Lu, J. F. Sherbourne, C. D.: 1994, Jan.
The mos 36-item short-form health survey (sf-36): Iii. tests of data quality, scaling assumptions, and reliability across diverse patient groups.
Med Care, 32(1), 40-66.
McHorney1993McHorney, C. A., Ware, J. E. Raczek, A. E.: 1993, Mar.
The mos 36-item short-form health survey (sf-36): Ii. psychometric and clinical tests of validity in measuring physical and mental health constructs.
Med Care, 31(3), 247-263.
Mesa2000Mesa, A., Diaz, A. P. Frosth, M.: 2000, Apr.
Narcolepsy and anesthesia.
Anesthesiology, 92(4), 1194-1196.
Mieda2004Mieda, M., Willie, J. T., Hara, J., Sinton, C. M., Sakurai, T. Yanagisawa, M.: 2004, Mar.
Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice.
Proc Natl Acad Sci U S A, 101(13), 4649-4654.
Mignot1998Mignot, E.: 1998, Feb.
Genetic and familial aspects of narcolepsy.
Neurology, 50(2 Suppl 1), S16-S22.
Mignot2001Mignot, E.: 2001, Nov.
A commentary on the neurobiology of the hypocretin/orexin system.
Neuropsychopharmacology, 25(5 Suppl), S5-13.
Mignot2004Mignot, E.: 2004, Jun.
Sleep, sleep disorders and hypocretin (orexin).
Sleep Med, 5 Suppl 1, S2-S8.
Mignot2002Mignot, E., Lammers, G. J., Ripley, B., Okun, M., Nevsimalova, S., Overeem, S. .: 2002, Oct.
The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
Arch Neurol, 59(10), 1553-1562.
Mignot2001aMignot, E., Lin, L., Rogers, W., Honda, Y., Qiu, X., Lin, X. .: 2001, Mar.
Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups.
Am J Hum Genet, 68(3), 686-699.
Mignot1994aMignot, E., Lin, X., Arrigoni, J., Macaubas, C., Olive, F., Hallmayer, J. .: 1994, Dec.
Dqb1*0602 and dqa1*0102 (dq1) are better markers than dr2 for narcolepsy in caucasian and black americans.
Sleep, 17(8 Suppl), S60-S67.
Mignot1993bMignot, E., Renaud, A., Nishino, S., Arrigoni, J., Guilleminault, C. Dement, W. C.: 1993.
Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers.
Psychopharmacology (Berl), 113(1), 76-82.
Mignot1995bMignot, E., Tafti, M., Dement, W. C. Grumet, F. C.: 1995.
Narcolepsy and immunity.
Adv Neuroimmunol, 5(1), 23-37.
Mignot1991Mignot, E., Wang, C., Rattazzi, C., Gaiser, C., Lovett, M., Guilleminault, C. .: 1991, Apr.
Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin heavy-chain switch-like segment.
Proc Natl Acad Sci U S A, 88(8), 3475-3478.
Mignot1998aMignot, E., Young, T., Lin, L., Finn, L. Palta, M.: 1998, Mar.
Reduction of REM sleep latency associated with HLA-DQB1*0602 in normal adults.
Lancet, 351(9104), 727.
Miller1990Miller, J. D., Faull, K. F., Bowersox, S. S. Dement, W. C.: 1990, Feb.
CNS monoamines and their metabolites in canine narcolepsy: a replication study.
Brain Res, 509(1), 169-171.
Miller1989Miller, N. S., Millman, R. B. Gold, M. S.: 1989.
Amphetamines: pharmacology, abuse and addiction.
Adv Alcohol Subst Abuse, 8(2), 53-69.
Mistlberger1983Mistlberger, R. E., Bergmann, B. M., Waldenar, W. Rechtschaffen, A.: 1983.
Recovery sleep following sleep deprivation in intact and suprachiasmatic nuclei-lesioned rats.
Sleep, 6(3), 217-233.
Mitler2000Mitler, Harsh, Hirshkowitz Guilleminault.: 2000, Jul.
Long-term efficacy and safety of modafinil (provigil((r))) for the treatment of excessive daytime sleepiness associated with narcolepsy.
Sleep Med, 1(3), 231-243.
Mitler1994Mitler, M. M.: 1994, Dec.
Evaluation of treatment with stimulants in narcolepsy.
Sleep, 17(8 Suppl), S103-S106.
Mitler1994aMitler, M. M., Aldrich, M. S., Koob, G. F. Zarcone, V. P.: 1994, Jun.
Narcolepsy and its treatment with stimulants. ASDA standards of practice.
Sleep, 17(4), 352-371.
Mitler1974Mitler, M. M., Boysen, B. G., Campbell, L. Dement, W. C.: 1974, Nov.
Narcolepsy-cataplexy in a female dog.
Exp Neurol, 45(2), 332-340.
Mitler1990Mitler, M. M., Hajdukovic, R., Erman, M. Koziol, J. A.: 1990, Jan.
Narcolepsy.
J Clin Neurophysiol, 7(1), 93-118.
Mitler1986Mitler, M. M., Shafor, R., Hajdukovich, R., Timms, R. M. Browman, C. P.: 1986.
Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline.
Sleep, 9(1 Pt 2), 260-264.
Mitler1998Mitler, M. M., Walsleben, J., Sangal, R. B. Hirshkowitz, M.: 1998, Jul.
Sleep latency on the maintenance of wakefulness test (mwt) for 530 patients with narcolepsy while free of psychoactive drugs.
Electroencephalogr Clin Neurophysiol, 107(1), 33-38.
Moldofsky2000aMoldofsky, Broughton Hill.: 2000, Apr.
A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy.
Sleep Med, 1(2), 109-116.
Montplaisir1986Montplaisir, J. Godbout, R.: 1986.
Nocturnal sleep of narcoleptic patients: revisited.
Sleep, 9(1 Pt 2), 159-161.
Morrish2004Morrish, E., King, M. A., Smith, I. E. Shneerson, J. M.: 2004, Jan.
Factors associated with a delay in the diagnosis of narcolepsy.
Sleep Med, 5(1), 37-41.
Moscovitch1993Moscovitch, A., Partinen, M. Guilleminault, C.: 1993, Jan.
The positive diagnosis of narcolepsy and narcolepsy's borderland.
Neurology, 43(1), 55-60.
Mosko1983Mosko, S. S., Holowach, J. B. Sassin, J. F.: 1983.
The 24-hour rhythm of core temperature in narcolepsy.
Sleep, 6(2), 137-146.
Nakano1995Nakano, H. Ogashiwa, M.: 1995, Feb.
Complete remission of narcolepsy after surgical treatment of an arachnoid cyst in the cerebellopontine angle.
J Neurol Neurosurg Psychiatry, 58(2), 264.
Nambu1999Nambu, T., Sakurai, T., Mizukami, K., Hosoya, Y., Yanagisawa, M. Goto, K.: 1999, May.
Distribution of orexin neurons in the adult rat brain.
Brain Res, 827(1-2), 243-260.
Nawrot2003Nawrot, P., Jordan, S., Eastwood, J., Rotstein, J., Hugenholtz, A. Feeley, M.: 2003, Jan.
Effects of caffeine on human health.
Food Addit Contam, 20(1), 1-30.
Nehlig1992Nehlig, A., Daval, J. L. Debry, G.: 1992.
Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects.
Brain Res Brain Res Rev, 17(2), 139-170.
Nevsimalova1997Nevsimalova, S., Mignot, E., Sonka, K. Arrigoni, J. L.: 1997, Nov.
Familial aspects of narcolepsy-cataplexy in the Czech Republic.
Sleep, 20(11), 1021-1026.
Nishino1993Nishino, S., Fruhstorfer, B., Arrigoni, J., Guilleminault, C., Dement, W. C. Mignot, E.: 1993, Mar.
Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy.
J Pharmacol Exp Ther, 264(3), 1079-1084.
Nishino2001Nishino, S., Fujiki, N., Ripley, B., Sakurai, E., Kato, M., Watanabe, T. .: 2001, Nov.
Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs.
Neurosci Lett, 313(3), 125-128.
Nishino1998Nishino, S., Mao, J., Sampathkumaran, R. Shelton, J.: 1998.
Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants.
Sleep Res Online, 1(1), 49-61.
Nishino1997aNishino, S. Mignot, E.: 1997, May.
Pharmacological aspects of human and canine narcolepsy.
Prog Neurobiol, 52(1), 27-78.
Nishino2000Nishino, S., Okura, M. Mignot, E.: 2000, Feb.
Narcolepsy: genetic predisposition and neuropharmacological mechanisms. REVIEW ARTICLE.
Sleep Med Rev, 4(1), 57-99.
Nishino2000aNishino, S., Riehl, J., Hong, J., Kwan, M., Reid, M. Mignot, E.: 2000, Dec.
Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans.
Neurosci Res, 38(4), 437-446.
Nishino2000bNishino, S., Ripley, B., Overeem, S., Lammers, G. J. Mignot, E.: 2000, Jan.
Hypocretin (orexin) deficiency in human narcolepsy.
Lancet, 355(9197), 39-40.
Nishino2001bNishino, S., Ripley, B., Overeem, S., Nevsimalova, S., Lammers, G. J., Vankova, J. .: 2001, Sep.
Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy.
Ann Neurol, 50(3), 381-388.
Nishino1995Nishino, S., Tafti, M., Reid, M. S., Shelton, J., Siegel, J. M., Dement, W. C. .: 1995, Jul.
Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy.
J Neurosci, 15(7 Pt 1), 4806-4814.
Nobili1996Nobili, L., Ferrillo, F., Besset, A., Rosadini, G., Schiavi, G. Billiard, M.: 1996.
Ultradian aspects of sleep in narcolepsy.
Neurophysiol Clin, 26(1), 51-59.
Okun2002aOkun, M. L., Lin, L., Pelin, Z., Hong, S. Mignot, E.: 2002, Feb.
Clinical aspects of narcolepsy-cataplexy across ethnic groups.
Sleep, 25(1), 27-35.
Oosterloo2006Oosterloo, M., Lammers, G. J., Overeem, S., Noord, I. de Kooij, J. J. S.: 2006, Aug.
Possible confusion between primary hypersomnia and adult attention-deficit/hyperactivity disorder.
Psychiatry Res, 143(2-3), 293-297.
Orellana1994Orellana, C., Villemin, E., Tafti, M., Carlander, B., Besset, A. Billiard, M.: 1994, Dec.
Life events in the year preceding the onset of narcolepsy.
Sleep, 17(8 Suppl), S50-S53.
Overeem2001Overeem, S., Mignot, E., Dijk, J. G. van Lammers, G. J.: 2001, Mar.
Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives.
J Clin Neurophysiol, 18(2), 78-105.
Pakola1995Pakola, S. J., Dinges, D. F. Pack, A. I.: 1995, Nov.
Review of regulations and guidelines for commercial and noncommercial drivers with sleep apnea and narcolepsy.
Sleep, 18(9), 787-796.
Parkes1994Parkes, D.: 1994, Dec.
Introduction to the mechanism of action of different treatments of narcolepsy.
Sleep, 17(8 Suppl), S93-S96.
Parkes1999Parkes, J. D.: 1999, Jun.
Genetic factors in human sleep disorders with special reference to Norrie disease, Prader-Willi syndrome and Moebius syndrome.
J Sleep Res, 8 Suppl 1, 14-22.
Parkes1998Parkes, J. D., Chen, S. Y., Clift, S. J., Dahlitz, M. J. Dunn, G.: 1998, Mar.
The clinical diagnosis of the narcoleptic syndrome.
J Sleep Res, 7(1), 41-52.
Parkes1995Parkes, J. D., Clift, S. J., Dahlitz, M. J., Chen, S. Y. Dunn, G.: 1995, Sep.
The narcoleptic syndrome.
J Neurol Neurosurg Psychiatry, 59(3), 221-224.
Parkes1986Parkes, J. D., Langdon, N. Lock, C.: 1986, Feb.
Narcolepsy and immunity.
Br Med J (Clin Res Ed), 292(6517), 359-360.
Pavel1980Pavel, S., Goldstein, R. Petrescu, M.: 1980.
Vasotocin, melatonin and narcolepsy: possible involvement of the pineal gland in its patho-physiological mechanism.
Peptides, 1(4), 281-284.
Peyron2000Peyron, C., Faraco, J., Rogers, W., Ripley, B., Overeem, S., Charnay, Y. .: 2000, Sep.
A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.
Nat Med, 6(9), 991-997.
Peyron1998Peyron, C., Tighe, D. K., Pol, A. N. van den, Lecea, L. de, Heller, H. C., Sutcliffe, J. G. .: 1998, Dec.
Neurons containing hypocretin (orexin) project to multiple neuronal systems.
J Neurosci, 18(23), 9996-10015.
Poceta1992Poceta, J. S., Timms, R. M., Jeong, D. U., Ho, S. L., Erman, M. K. Mitler, M. M.: 1992, Apr.
Maintenance of wakefulness test in obstructive sleep apnea syndrome.
Chest, 101(4), 893-897.
Pol1998aPol, A. N. van den, Gao, X. B., Obrietan, K., Kilduff, T. S. Belousov, A. B.: 1998, Oct.
Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin.
J Neurosci, 18(19), 7962-7971.
Pollak1992Pollak, C. P., Wagner, D. R., Moline, M. L. Monk, T. H.: 1992, Jun.
Cognitive and motor performance of narcoleptic and normal subjects living in temporal isolation.
Sleep, 15(3), 202-211.
1994Practice parameters for the use of stimulants in the treatment of narcolepsy. standards of practice committee of the american sleep disorders association.: 1994, Jun.
Sleep, 17(4), 348-351.
Price1981Price, J. L. Amaral, D. G.: 1981, Nov.
An autoradiographic study of the projections of the central nucleus of the monkey amygdala.
J Neurosci, 1(11), 1242-1259.
2002A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy.: 2002, Feb.
Sleep, 25(1), 42-49.
2000Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: Us modafinil in narcolepsy multicenter study group.: 2000, Mar.
Neurology, 54(5), 1166-1175.
RECHTSCHAFFEN1963bRechtschaffen, A., Wolpert, E. A., Dement, W. C., Mitchell, S. A. Fisher, C.: 1963, Aug.
NOCTURNAL SLEEP OF NARCOLEPTICS.
Electroencephalogr Clin Neurophysiol, 15, 599-609.
Reid1994cReid, M. S., Tafti, M., Geary, J. N., Nishino, S., Siegel, J. M., Dement, W. C. .: 1994, Apr.
Cholinergic mechanisms in canine narcolepsy-I. Modulation of cataplexy via local drug administration into the pontine reticular formation.
Neuroscience, 59(3), 511-522.
Reimer1999Reimer, M. Flemons, W.: 1999.
Measuring quality of live in disorders of sleep and breathing.
Sleep Breath, 3(4), 139-146.
Reimer2003Reimer, M. A. Flemons, W. W.: 2003, Aug.
Quality of life in sleep disorders.
Sleep Med Rev, 7(4), 335-349.
Ricaurte1984aRicaurte, G. A., Guillery, R. W., Seiden, L. S. Schuster, C. R.: 1984, Jan.
Nerve terminal degeneration after a single injection of d-amphetamine in iprindole-treated rats: relation to selective long-lasting dopamine depletion.
Brain Res, 291(2), 378-382.
Ricaurte1984Ricaurte, G. A., Seiden, L. S. Schuster, C. R.: 1984, Jun.
Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers.
Brain Res, 303(2), 359-364.
Rieger2003Rieger, M., Mayer, G. Gauggel, S.: 2003, Feb.
Attention deficits in patients with narcolepsy.
Sleep, 26(1), 36-43.
Riehl1998Riehl, J., Nishino, S., Cederberg, R., Dement, W. C. Mignot, E.: 1998, Aug.
Development of cataplexy in genetically narcoleptic Dobermans.
Exp Neurol, 152(2), 292-302.
Ripley2001Ripley, B., Fujiki, N., Okura, M., Mignot, E. Nishino, S.: 2001, Jun.
Hypocretin levels in sporadic and familial cases of canine narcolepsy.
Neurobiol Dis, 8(3), 525-534.
Robertson2000Robertson, P., DeCory, H. H., Madan, A. Parkinson, A.: 2000, Jun.
In vitro inhibition and induction of human hepatic cytochrome p450 enzymes by modafinil.
Drug Metab Dispos, 28(6), 664-671.
Rogers1984Rogers, A. E.: 1984, Dec.
Problems and coping strategies identified by narcoleptic patients.
J Neurosurg Nurs, 16(6), 326-334.
Rogers1997dRogers, A. E., Aldrich, M. S., Berrios, A. M. Rosenberg, R. S.: 1997, Jan.
Compliance with stimulant medications in patients with narcolepsy.
Sleep, 20(1), 28-33.
Rogers1990Rogers, A. E. Rosenberg, R. S.: 1990, Feb.
Tests of memory in narcoleptics.
Sleep, 13(1), 42-52.
Rolls1979aRolls, E. T., Sanghera, M. K. Roper-Hall, A.: 1979, Mar.
The latency of activation of neurones in the lateral hypothalamus and substantia innominata during feeding in the monkey.
Brain Res, 164, 121-135.
Roth1968Roth, B., Buůhová, S. Berková, L.: 1968.
Familial sleep paralysis.
Schweiz Arch Neurol Neurochir Psychiatr, 102(2), 321-330.
Roth1980aRoth, T., Hartse, K. M., Zorick, F. Conway, W.: 1980.
Multiple naps and the evaluation of daytime sleepiness in patients with upper airway sleep apnea.
Sleep, 3(3-4), 425-439.
Rugino2001Rugino, T. A. Copley, T. C.: 2001, Feb.
Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study.
J Am Acad Child Adolesc Psychiatry, 40(2), 230-235.
Rye1998Rye, D. B., Dihenia, B., Weissman, J. D., Epstein, C. M. Bliwise, D. L.: 1998, Feb.
Presentation of narcolepsy after 40.
Neurology, 50(2), 459-465.
Sakurai2005Sakurai, T.: 2005, Aug.
Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis.
Sleep Med Rev, 9(4), 231-241.
Sakurai1998aSakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H. .: 1998, Feb.
Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.
Cell, 92(4), 573-585.
Sakurai1999aSakurai, T., Moriguchi, T., Furuya, K., Kajiwara, N., Nakamura, T., Yanagisawa, M. .: 1999, Jun.
Structure and function of human prepro-orexin gene.
J Biol Chem, 274(25), 17771-17776.
Pascual2001Salin-Pascual, R., Gerashchenko, D., Greco, M., Blanco-Centurion, C. Shiromani, P. J.: 2001, Nov.
Hypothalamic regulation of sleep.
Neuropsychopharmacology, 25(5 Suppl), S21-S27.
Salomon2003Salomon, R. M., Ripley, B., Kennedy, J. S., Johnson, B., Schmidt, D., Zeitzer, J. M. .: 2003, Jul.
Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects.
Biol Psychiatry, 54(2), 96-104.
Sangal1999Sangal, R. B., Mitler, M. M. Sangal, J. M.: 1999, Dec.
Subjective sleepiness ratings (epworth sleepiness scale) do not reflect the same parameter of sleepiness as objective sleepiness (maintenance of wakefulness test) in patients with narcolepsy.
Clin Neurophysiol, 110(12), 2131-2135.
Sangal1999cSangal, R. B., Sangal, J. M. Belisle, C.: 1999, Apr.
Subjective and objective indices of sleepiness (ess and mwt) are not equally useful in patients with sleep apnea.
Clin Electroencephalogr, 30(2), 73-75.
Sangal1992Sangal, R. B., Thomas, L. Mitler, M. M.: 19921, Sep.
Disorders of excessive sleepiness. treatment improves ability to stay awake but does not reduce sleepiness.
Chest, 102(3), 699-703.
Sangal1992aSangal, R. B., Thomas, L. Mitler, M. M.: 19922, Apr.
Maintenance of wakefulness test and multiple sleep latency test. measurement of different abilities in patients with sleep disorders.
Chest, 101(4), 898-902.
Saper2001Saper, C. B., Chou, T. C. Scammell, T. E.: 2001, Dec.
The sleep switch: hypothalamic control of sleep and wakefulness.
Trends Neurosci, 24(12), 726-731.
Scammell2000Scammell, T. E., Estabrooke, I. V., McCarthy, M. T., Chemelli, R. M., Yanagisawa, M., Miller, M. S. .: 2000, Nov.
Hypothalamic arousal regions are activated during modafinil-induced wakefulness.
J Neurosci, 20(22), 8620-8628.
Scharf1985Scharf, M. B., Brown, D., Woods, M., Brown, L. Hirschowitz, J.: 1985, Jun.
The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy.
J Clin Psychiatry, 46(6), 222-225.
Schneider1994Schneider, L. S., Tariot, P. N. Goldstein, B.: 1994, Dec.
Therapy with l-deprenyl (selegiline) and relation to abuse liability.
Clin Pharmacol Ther, 56(6 Pt 2), 750-756.
Schuld2000bSchuld, A., Hebebrand, J., Geller, F. Pollmächer, T.: 2000, Apr.
Increased body-mass index in patients with narcolepsy.
Lancet, 355(9211), 1274-1275.
Schulz1995bSchulz Wilde-Frenz.: 1995, Mar.
Symposium: Cognitive processes and sleep disturbances: The disturbance of cognitive processes in narcolepsy.
J Sleep Res, 4(1), 10-14.
Schwartz2003aSchwartz, J. R. L., Feldman, N. T., Fry, J. M. Harsh, J.: 2003, Jan.
Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants.
Sleep Med, 4(1), 43-49.
Scrima1989Scrima, L., Hartman, P. G., Johnson, F. H. Hiller, F. C.: 1989, Aug.
Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures.
Biol Psychiatry, 26(4), 331-343.
Scrima1990Scrima, L., Hartman, P. G., Johnson, F. H., Thomas, E. E. Hiller, F. C.: 1990, Dec.
The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study.
Sleep, 13(6), 479-490.
Shoham1982Shoham, S. Teitelbaum, P.: 1982, Feb.
Subcortical waking and sleep during lateral hypothalamic "somnolence" in rats.
Physiol Behav, 28(2), 323-333.
Siegel1999Siegel, J. M.: 1999, Aug.
Narcolepsy: a key role for hypocretins (orexins).
Cell, 98(4), 409-412.
Siegel2001Siegel, J. M., Moore, R., Thannickal, T. Nienhuis, R.: 2001, Nov.
A brief history of hypocretin/orexin and narcolepsy.
Neuropsychopharmacology, 25(5 Suppl), S14-S20.
Siegel1992Siegel, J. M., Nienhuis, R., Fahringer, H. M., Chiu, C., Dement, W. C., Mignot, E. .: 1992, May.
Activity of medial mesopontine units during cataplexy and sleep-waking states in the narcoleptic dog.
J Neurosci, 12(5), 1640-1646.
Siegel1991Siegel, J. M., Nienhuis, R., Fahringer, H. M., Paul, R., Shiromani, P., Dement, W. C. .: 1991, May.
Neuronal activity in narcolepsy: identification of cataplexy-related cells in the medial medulla.
Science, 252(5010), 1315-1318.
Silber2002Silber, M. H., Krahn, L. E. Olson, E. J.: 2002, Mar.
Diagnosing narcolepsy: validity and reliability of new diagnostic criteria.
Sleep Med, 3(2), 109-113.
Smit2005Smit, A. S., Fortuyn, H. A. D., Eling, P. A. T. M. Coenen, A. M. L.: 2005, Dec.
Diurnal spectral EEG fluctuations in narcoleptic patients during rest and reaction time tasks.
J Sleep Res, 14(4), 455-461.
Sonsalla1988aSonsalla, P. K. Heikkila, R. E.: 1988.
Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp) and methamphetamine in several strains of mice.
Prog Neuropsychopharmacol Biol Psychiatry, 12(2-3), 345-354.
Sweere1998Sweere, Y., Kerkhof, G. A., Weerd, A. W. D., Kamphuisen, H. A., Kemp, B. Schimsheimer, R. J.: 1998, Dec.
The validity of the dutch sleep disorders questionnaire (sdq).
J Psychosom Res, 45(6), 549-555.
Taheri2002Taheri, S. Mignot, E.: 2002, Aug.
The genetics of sleep disorders.
Lancet Neurol, 1(4), 242-250.
Tanganelli1992Tanganelli, S., Fuxe, K., Ferraro, L., Janson, A. M. Bianchi, C.: 1992, Apr.
Inhibitory effects of the psychoactive drug modafinil on gamma-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involvement of 5-hydroxytryptamine mechanisms.
Naunyn Schmiedebergs Arch Pharmacol, 345(4), 461-465.
Taylor2000Taylor, F. B. Russo, J.: 2000.
Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults.
J Child Adolesc Psychopharmacol, 10(4), 311-320.
Teixeira2004aTeixeira, V. G., Faccenda, J. F. Douglas, N. J.: 2004, Sep.
Functional status in patients with narcolepsy.
Sleep Med, 5(5), 477-483.
Thannickal2000Thannickal, T. C., Moore, R. Y., Nienhuis, R., Ramanathan, L., Gulyani, S., Aldrich, M. .: 2000, Sep.
Reduced number of hypocretin neurons in human narcolepsy.
Neuron, 27(3), 469-474.
Thirumalai2000Thirumalai Shubin.: 2000, Oct.
The use of citalopram in resistant cataplexy.
Sleep Med, 1(4), 313-316.
Thorpy2001Thorpy.: 2001, Jan.
Current concepts in the etiology, diagnosis and treatment of narcolepsy.
Sleep Med, 2(1), 5-17.
Thorpy2003Thorpy, M. J., Schwartz, J. R. L., Kovacevic-Ristanovic, R. Hayduk, R.: 2003, Jun.
Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies.
Psychopharmacology (Berl), 167(4), 380-385.
Trivedi1998Trivedi, P., Yu, H., MacNeil, D. J., Ploeg, L. H. V. der Guan, X. M.: 1998, Oct.
Distribution of orexin receptor mRNA in the rat brain.
FEBS Lett, 438(1-2), 71-75.
Valley1981Valley, V. Broughton, R.: 1981, Sep.
Daytime performance deficits and physiological vigilance in untreated patients with narcolepsy-cataplexy compared to controls.
Rev Electroencephalogr Neurophysiol Clin, 11(1), 133-139.
Valley1983Valley, V. Broughton, R.: 1983, Mar.
The physiological (eeg) nature of drowsiness and its relation to performance deficits in narcoleptics.
Electroencephalogr Clin Neurophysiol, 55(3), 243-251.
Vandeputte2003Vandeputte, M. Weerd, A. de.: 2003, Jul.
Sleep disorders and depressive feelings: a global survey with the beck depression scale.
Sleep Med, 4(4), 343-345.
Vgontzas1997Vgontzas, A. N., Papanicolaou, D. A., Bixler, E. O., Kales, A., Tyson, K. Chrousos, G. P.: 1997, May.
Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity.
J Clin Endocrinol Metab, 82(5), 1313-1316.
Vignatelli2004Vignatelli, L., D'Alessandro, R., Mosconi, P., Ferini-Strambi, L., Guidolin, L., Vincentiis, A. D. .: 2004, Sep.
Health-related quality of life in italian patients with narcolepsy: the sf-36 health survey.
Sleep Med, 5(5), 467-475.
VOGEL1960Vogel, G.: 1960, Oct.
Studies in psychophysiology of dreams. III. The dream of narcolepsy.
Arch Gen Psychiatry, 3, 421-428.
Volk1990Volk, S., Schulz, H., Yassouridis, A., Wilde-Frenz, J. Simon, O.: 1990, Apr.
The influence of two behavioral regimens on the distribution of sleep and wakefulness in narcoleptic patients.
Sleep, 13(2), 136-142.
Wagner1980Wagner, G. C., Ricaurte, G. A., Johanson, C. E., Schuster, C. R. Seiden, L. S.: 1980, May.
Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in caudate.
Neurology, 30(5), 547-550.
Wallace1992Wallace, D. M., Magnuson, D. J. Gray, T. S.: 1992, Mar.
Organization of amygdaloid projections to brainstem dopaminergic, noradrenergic, and adrenergic cell groups in the rat.
Brain Res Bull, 28(3), 447-454.
Ware1996Ware, J., Kosinski, M. Keller, S. D.: 1996, Mar.
A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity.
Med Care, 34(3), 220-233.
Ware1998cWare, J. E. Gandek, B.: 1998, Nov.
Overview of the sf-36 health survey and the international quality of life assessment (iqola) project.
J Clin Epidemiol, 51(11), 903-912.
Weaver1997Weaver, T. E., Laizner, A. M., Evans, L. K., Maislin, G., Chugh, D. K., Lyon, K. .: 1997, Oct.
An instrument to measure functional status outcomes for disorders of excessive sleepiness.
Sleep, 20(10), 835-843.
Willie2003Willie, J. T., Chemelli, R. M., Sinton, C. M., Tokita, S., Williams, S. C., Kisanuki, Y. Y. .: 2003, Jun.
Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes.
Neuron, 38(5), 715-730.
Willie2001Willie, J. T., Chemelli, R. M., Sinton, C. M. Yanagisawa, M.: 2001.
To eat or to sleep? Orexin in the regulation of feeding and wakefulness.
Annu Rev Neurosci, 24, 429-458.
Wing2000Wing, Y. K., Li, R. H., Ho, C. K., Fong, S. Y., Chow, L. Y. Leung, T.: 2000, Nov.
A validity study of ullanlinna narcolepsy scale in hong kong chinese.
J Psychosom Res, 49(5), 355-361.
Wise1998Wise, M. S.: 1998, Feb.
Childhood narcolepsy.
Neurology, 50(2 Suppl 1), S37-S42.
Wisor2001Wisor, J. P., Nishino, S., Sora, I., Uhl, G. H., Mignot, E. Edgar, D. M.: 2001, Mar.
Dopaminergic role in stimulant-induced wakefulness.
J Neurosci, 21(5), 1787-1794.
Wong1998bWong, Y. N., King, S. P., Laughton, W. B., McCormick, G. C. Grebow, P. E.: 1998, Mar.
Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers.
J Clin Pharmacol, 38(3), 276-282.
Wong1999aWong, Y. N., Simcoe, D., Hartman, L. N., Laughton, W. B., King, S. P., McCormick, G. C. .: 1999, Jan.
A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers.
J Clin Pharmacol, 39(1), 30-40.
Wong1998Wong, Y. N., Wang, L., Hartman, L., Simcoe, D., Chen, Y., Laughton, W. .: 1998, Oct.
Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers.
J Clin Pharmacol, 38(10), 971-978.
Wu1999Wu, M. F., Gulyani, S. A., Yau, E., Mignot, E., Phan, B. Siegel, J. M.: 1999.
Locus coeruleus neurons: cessation of activity during cataplexy.
Neuroscience, 91(4), 1389-1399.
Wurtman2006Wurtman, R. J.: 2006, Oct.
Narcolepsy and the hypocretins.
Metabolism, 55(10 Suppl 2), S36-S39.
Yamanaka2003Yamanaka, A., Beuckmann, C. T., Willie, J. T., Hara, J., Tsujino, N., Mieda, M. .: 2003, Jun.
Hypothalamic orexin neurons regulate arousal according to energy balance in mice.
Neuron, 38(5), 701-713.
Yamanaka2002Yamanaka, A., Tsujino, N., Funahashi, H., Honda, K., Guan, J. lian, Wang, Q.-P. .: 2002, Feb.
Orexins activate histaminergic neurons via the orexin 2 receptor.
Biochem Biophys Res Commun, 290(4), 1237-1245.
Yoshida2001Yoshida, Y., Fujiki, N., Nakajima, T., Ripley, B., Matsumura, H., Yoneda, H. .: 2001, Oct.
Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities.
Eur J Neurosci, 14(7), 1075-1081.
Yuan1997Yuan, J., McCann, U. Ricaurte, G.: 1997, Aug.
Methylphenidate and brain dopamine neurotoxicity.
Brain Res, 767(1), 172-175.
Zaczek1989Zaczek, R., Battaglia, G., Contrera, J. F., Culp, S. Souza, E. B. D.: 1989, Sep.
Methylphenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine.
Toxicol Appl Pharmacol, 100(2), 227-233.
Zeitzer2006Zeitzer, J. M., Nishino, S. Mignot, E.: 2006, Jul.
The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions.
Trends Pharmacol Sci, 27(7), 368-374.

Vincent de Groot 2007-05-20